The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer.
Although phase III trials have reported improved overall survival in patients with advanced esophageal squamous cell carcinoma following treatment with nivolumab, as compared with chemotherapy (paclitaxel or docetaxel), the treatment was effective only in a limited number of patients. Therefore, the...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0285365 |
| _version_ | 1797805684400586752 |
|---|---|
| author | Naoki Takegawa Taku Hirabayashi Shunta Tanaka Michiko Nishikawa Nagahiro Tokuyama Takuya Mimura Saeko Kushida Hidetaka Tsumura Yoshinobu Yamamoto Ikuya Miki Masahiro Tsuda |
| author_facet | Naoki Takegawa Taku Hirabayashi Shunta Tanaka Michiko Nishikawa Nagahiro Tokuyama Takuya Mimura Saeko Kushida Hidetaka Tsumura Yoshinobu Yamamoto Ikuya Miki Masahiro Tsuda |
| author_sort | Naoki Takegawa |
| collection | DOAJ |
| description | Although phase III trials have reported improved overall survival in patients with advanced esophageal squamous cell carcinoma following treatment with nivolumab, as compared with chemotherapy (paclitaxel or docetaxel), the treatment was effective only in a limited number of patients. Therefore, the aim of this study is to determine whether there is a correlation between nutritional status (Glasgow prognostic score, prognostic nutritional index, and neutrophil-to-lymphocyte ratio) and prognosis of advanced esophageal cancer in patients treated with taxane or nivolumab therapy. The medical records of 35 patients who received taxane monotherapy (paclitaxel or docetaxel), for advanced esophageal cancer between October 2016 and November 2018 (taxane cohort) were reviewed. The clinical data of 37 patients who received nivolumab therapy between March 2020 and September 2021 (nivolumab cohort) were collected. The median overall survival was 9.1 months for the taxane cohort and 12.5 months for the nivolumab cohort. In the nivolumab cohort, patients with good nutritional status had significantly better median overall survival than those with poor nutritional status (18.1 vs. 7.6 months, respectively, p = 0.009, classified by prognostic nutritional index, 15.5 vs. 4.3 months, respectively, p = 0.012, classified by Glasgow prognostic score), whereas the prognosis of the patients treated with taxane therapy was less affected by the nutritional status. This suggests that the pretreatment nutritional status of patients with advanced esophageal cancer is a key factor for successful outcomes, especially for treatment with nivolumab. |
| first_indexed | 2024-03-13T05:55:47Z |
| format | Article |
| id | doaj.art-3c58d9e7e03440a2a26429525c5507ce |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-13T05:55:47Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3c58d9e7e03440a2a26429525c5507ce2023-06-13T05:31:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01185e028536510.1371/journal.pone.0285365The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer.Naoki TakegawaTaku HirabayashiShunta TanakaMichiko NishikawaNagahiro TokuyamaTakuya MimuraSaeko KushidaHidetaka TsumuraYoshinobu YamamotoIkuya MikiMasahiro TsudaAlthough phase III trials have reported improved overall survival in patients with advanced esophageal squamous cell carcinoma following treatment with nivolumab, as compared with chemotherapy (paclitaxel or docetaxel), the treatment was effective only in a limited number of patients. Therefore, the aim of this study is to determine whether there is a correlation between nutritional status (Glasgow prognostic score, prognostic nutritional index, and neutrophil-to-lymphocyte ratio) and prognosis of advanced esophageal cancer in patients treated with taxane or nivolumab therapy. The medical records of 35 patients who received taxane monotherapy (paclitaxel or docetaxel), for advanced esophageal cancer between October 2016 and November 2018 (taxane cohort) were reviewed. The clinical data of 37 patients who received nivolumab therapy between March 2020 and September 2021 (nivolumab cohort) were collected. The median overall survival was 9.1 months for the taxane cohort and 12.5 months for the nivolumab cohort. In the nivolumab cohort, patients with good nutritional status had significantly better median overall survival than those with poor nutritional status (18.1 vs. 7.6 months, respectively, p = 0.009, classified by prognostic nutritional index, 15.5 vs. 4.3 months, respectively, p = 0.012, classified by Glasgow prognostic score), whereas the prognosis of the patients treated with taxane therapy was less affected by the nutritional status. This suggests that the pretreatment nutritional status of patients with advanced esophageal cancer is a key factor for successful outcomes, especially for treatment with nivolumab.https://doi.org/10.1371/journal.pone.0285365 |
| spellingShingle | Naoki Takegawa Taku Hirabayashi Shunta Tanaka Michiko Nishikawa Nagahiro Tokuyama Takuya Mimura Saeko Kushida Hidetaka Tsumura Yoshinobu Yamamoto Ikuya Miki Masahiro Tsuda The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. PLoS ONE |
| title | The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. |
| title_full | The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. |
| title_fullStr | The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. |
| title_full_unstemmed | The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. |
| title_short | The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. |
| title_sort | impact of nutritional status in nivolumab treated patients with advanced esophageal cancer |
| url | https://doi.org/10.1371/journal.pone.0285365 |
| work_keys_str_mv | AT naokitakegawa theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT takuhirabayashi theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT shuntatanaka theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT michikonishikawa theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT nagahirotokuyama theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT takuyamimura theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT saekokushida theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT hidetakatsumura theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT yoshinobuyamamoto theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT ikuyamiki theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT masahirotsuda theimpactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT naokitakegawa impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT takuhirabayashi impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT shuntatanaka impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT michikonishikawa impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT nagahirotokuyama impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT takuyamimura impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT saekokushida impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT hidetakatsumura impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT yoshinobuyamamoto impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT ikuyamiki impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer AT masahirotsuda impactofnutritionalstatusinnivolumabtreatedpatientswithadvancedesophagealcancer |